What we're seeing at JPM so far: Upcoming BD moves, pipeline updates and more
SAN FRANCISCO — After two years of Covid-stalled virtual dealmaking, the JP Morgan Healthcare Conference returned as an in-person event on Monday, with plenty of excitement in the air.
Attendees crammed into the Westin St. Francis, clogging the hallways with few masks on faces, to listen to pharma and biotech execs offer their latest positive news and expectations for 2023. Bristol Myers Squibb and Biogen drew standing room only crowds but offered few new updates. Protesters chanted briefly outside the hotel accusing Gilead of price-gouging their HIV drugs and left by lunchtime. The line for free lunch stretched hundreds of people long, wrapping around the conference rooms.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.